Related references
Note: Only part of the references are listed.Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer
Robert L. Ferris et al.
CLINICAL CANCER RESEARCH (2022)
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
F. L. Locke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Vaccine Strategies for Human Papillomavirus-Associated Head and Neck Cancers
Jade Z. Zhou et al.
CANCERS (2022)
Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment
Paula Dobosz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential
Wujun Chen et al.
FRONTIERS IN IMMUNOLOGY (2022)
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Manali Kamdar et al.
LANCET (2022)
Drosophila melanogaster: A platform for anticancer drug discovery and personalized therapies
Chamone Munnik et al.
FRONTIERS IN GENETICS (2022)
PD-L1 expression in head and neck cancer tissue specimens decreases with time
Georgia Karpathiou et al.
PATHOLOGY RESEARCH AND PRACTICE (2022)
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study
Sara Ghorashian et al.
LANCET HAEMATOLOGY (2022)
Targeting interleukin 6 signaling by monoclonal antibody siltuximab on cholangiocarcinoma
Mai Ly Thi Nguyen et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Personalized cancer vaccination in head and neck cancer
Hirofumi Shibata et al.
CANCER SCIENCE (2021)
Pembrolizumab in the first-line treatment of advanced head and neck cancer
Luana Guimaraes de Sousa et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis
Arushi Khurana et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies
Bethany Bareham et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Vaccine-Based Immunotherapy for Head and Neck Cancers
Simon Beyaert et al.
CANCERS (2021)
CAR-T cell therapy: current limitations and potential strategies
Robert C. Sterner et al.
BLOOD CANCER JOURNAL (2021)
Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G. Berdeja et al.
LANCET (2021)
Advances in Adoptive Cell Therapy for Head and Neck Cancer
Scott M. Norberg et al.
OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA (2021)
Interleukins in cancer: from biology to therapy
Dania Briukhovetska et al.
NATURE REVIEWS CANCER (2021)
MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma
Zi Mei et al.
CANCER MEDICINE (2020)
Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma
Maike Effern et al.
IMMUNITY (2020)
Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy
Koji Nagaoka et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
Jacob H. Rasmussen et al.
BRITISH JOURNAL OF CANCER (2019)
CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies
Lynsey M. Whilding et al.
CANCERS (2019)
T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study
Stacey L. Doran et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cancer targeting by TCR gene-engineered T cells directed against Kita-Kyushu Lung Cancer Antigen-1
Bridget Marcinkowski et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
IL-1 and IL-1 regulatory pathways in cancer progression and therapy
Alberto Mantovani et al.
IMMUNOLOGICAL REVIEWS (2018)
Glycan-directed CAR-T cells
Catharina Steentoft et al.
GLYCOBIOLOGY (2018)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
Nikolaos Zacharakis et al.
NATURE MEDICINE (2018)
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
M. R. Migden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma
Yuk Pheel Park et al.
ORAL ONCOLOGY (2018)
High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers
Muhammad Baghdadi et al.
SCIENTIFIC REPORTS (2018)
IL-23 and IL-1β Drive Human Th17 Cell Differentiation and Metabolic Reprogramming in Absence of CD28 Costimulation
Shankar Revu et al.
CELL REPORTS (2018)
Interleukin (IL)-6 Inhibits IL-27-and IL-30-Mediated Inflammatory Responses in Human Monocytes
Carlene Petes et al.
FRONTIERS IN IMMUNOLOGY (2018)
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
Arianna Calcinotto et al.
NATURE (2018)
IκBζ is a key transcriptional regulator of IL-36-driven psoriasis-related gene expression in keratinocytes
Anne Mueller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas
Yibo Yin et al.
MOLECULAR THERAPY-ONCOLYTICS (2018)
The IL-31/IL-31 receptor axis: general features and role in tumor microenvironment
Elisa Ferretti et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2017)
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M. Ridker et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2017)
Dual Roles of IL-27 in Cancer Biology and Immunotherapy
Marina Fabbi et al.
MEDIATORS OF INFLAMMATION (2017)
Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression
Kazuki Takada et al.
PLOS ONE (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Enfu Hui et al.
SCIENCE (2017)
Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models
Melinda Mata et al.
CANCER DISCOVERY (2017)
SOCS3 inhibits the pathological effects of IL-22 in nonmelanoma skin tumor-derived keratinocytes
Stefania Madonna et al.
ONCOTARGET (2017)
Interleukin-9 Promotes Pancreatic Cancer Cells Proliferation and Migration via the miR-200a/Beta-Catenin Axis
Bangli Hu et al.
BIOMED RESEARCH INTERNATIONAL (2017)
The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling
G. Nappo et al.
ONCOGENESIS (2017)
Global Manufacturing of CAR T Cell Therapy
Bruce L. Levine et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2017)
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
A. Necchi et al.
ANNALS OF ONCOLOGY (2017)
Interleukin-8 in cancer pathogenesis, treatment and follow-up
Carlos Alfaro et al.
CANCER TREATMENT REVIEWS (2017)
Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies
Jeong A. Park et al.
CANCER TREATMENT REVIEWS (2017)
Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma
R. H. Prabhala et al.
LEUKEMIA (2016)
Interleukin-30 Promotes Breast Cancer Growth and Progression
Irma Airoldi et al.
CANCER RESEARCH (2016)
The urgent need to recover MHC class I in cancers for effective immunotherapy
Federico Garrido et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Biology and clinical application of CAR T cells for B cell malignancies
Marco L. Davila et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape (Publication with Expression of Concern. See vol. 129, pg. 3464, 2019)
Meenakshi Hegde et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia
Noelle V. Frey et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
The paradoxical role of IL-10 in immunity and cancer
Mark H. Mannino et al.
CANCER LETTERS (2015)
Interleukin-5 Facilitates Lung Metastasis by Modulating the Immune Microenvironment
R. Zaynagetdinov et al.
CANCER RESEARCH (2015)
Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer
Cameron N. Johnstone et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2015)
Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance
Douglas C. Palmer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Opposing roles of STAT1 and STAT3 in IL-21 function in CD4+ T cells
Chi-Keung Wan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy
Bernice Lo et al.
SCIENCE (2015)
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
Robert Z. Orlowski et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Adoptive T Cell Immunotherapy for Cancer
Karlo Perica et al.
RAMBAM MAIMONIDES MEDICAL JOURNAL (2015)
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
Sonia Guedan et al.
BLOOD (2014)
Interleukin 18 activates MAPKs and STAT3 but not NF-κB in hippocampal HT-22 cells.
Silvia Alboni et al.
BRAIN BEHAVIOR AND IMMUNITY (2014)
Mechanisms and Functions of Inflammasomes
Mohamed Lamkanfi et al.
CELL (2014)
Regulation of Cellular Processes by Interleukin-16 in Homeostasis and Cancer
Jillian Richmond et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
The Role of Interleukin 17 in Tumour Proliferation, Angiogenesis, and Metastasis
Bob Yang et al.
MEDIATORS OF INFLAMMATION (2014)
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Manuel Hidalgo et al.
CANCER DISCOVERY (2014)
Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
D. McDermott et al.
ANNALS OF ONCOLOGY (2013)
Interleukin-20 Promotes Migration of Bladder Cancer Cells through Extracellular Signal-regulated Kinase (ERK)-mediated MMP-9 Protein Expression Leading to Nuclear Factor (NF-κB) Activation by Inducing the Up-regulation of p21WAF1 Protein Expression
Se-Jung Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Tumor-Derived IL-35 Promotes Tumor Growth by Enhancing Myeloid Cell Accumulation and Angiogenesis
Zhihui Wang et al.
JOURNAL OF IMMUNOLOGY (2013)
Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma
Meenakshi Hegde et al.
MOLECULAR THERAPY (2013)
Upregulated IL-19 in Breast Cancer Promotes Tumor Progression and Affects Clinical Outcome
Chung-Hsi Hsing et al.
CLINICAL CANCER RESEARCH (2012)
IL-33/ST2 axis in innate and acquired immunity to tumors
Ivan P. Jovanovic et al.
ONCOIMMUNOLOGY (2012)
OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells
Andreas A. Hombach et al.
ONCOIMMUNOLOGY (2012)
Pro-survival signaling via CD27 costimulation drives effective CAR T-cell therapy
De-Gang Song et al.
ONCOIMMUNOLOGY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg et al.
CLINICAL CANCER RESEARCH (2011)
Type III IFN Interleukin-28 Mediates the Antitumor Efficacy of Oncolytic Virus VSV in Immune-Competent Mouse Models of Cancer
Phonphimon Wongthida et al.
CANCER RESEARCH (2010)
Natural immunity to cancer in humans
Gabriela Bindea et al.
CURRENT OPINION IN IMMUNOLOGY (2010)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Immune infiltration in human tumors: a prognostic factor that should not be ignored
F. Pages et al.
ONCOGENE (2010)
The role of the novel Th17 cytokine IL-26 in intestinal inflammation
J. Dambacher et al.
GUT (2009)
Overexpression of Interleukin-1β Induces Gastric Inflammation and Cancer and Mobilizes Myeloid-Derived Suppressor Cells in Mice
Shuiping Tu et al.
CANCER CELL (2008)
IL-24: a classic cytokine and/or a potential cure for cancer?
S. Kreis et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2008)
Immune-mediated dormancy: an equilibrium with cancer
Michele W. L. Teng et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2008)
Induction of autoimmune disease in CTLA-4-/- mice depends on a specific CD28 motif that is required for in vivo costimulation
Xuguang Tai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Methods and protocols for prediction of immunogenic epitopes
Joo Chuan Tong et al.
BRIEFINGS IN BIOINFORMATICS (2007)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Role of IL-13 in regulation of anti-tumor immunity and tumor growth
M Terabe et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Share Paper
